eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company’s lead product candidate ...
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free ...
A biotechnology company using selective tranlsation regulation inhibitors to treat cancer is going public in a SPAC deal. A PIPE of $60 million is part of the SPAC merger and includes an investment ...
In a recent study posted to the bioRxiv* server, researchers determined which specific fragment crystallizable (Fc) effector functions protect against severe acute respiratory syndrome coronavirus 2 ...
Though it’s the robot arms and architecture that get most of the attention, the end effectors (or end-of-arm tooling) is where the action happens…or doesn’t happen if the end effector can’t adapt to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback